High Cerebrospinal <scp>DOPA</scp> Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease
Movement Disorders Clinical Practice, 2025
Sturchio A., Paslawski W., Khosousi S., Markaki I., Nalls M., Singleton A., Iwaki H., Svenningsson P.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology | Patient Stratification | CSF |  Olink Target 96 |
Abstract
Background
DOPA decarboxylase (DDC) in cerebrospinal fluid (CSF) is an emerging Parkinson’s disease (PD) biomarker, but its association with nonmotor symptoms is unclear.
Objectives
We aimed to determine if baseline DDC was associated with future cognitive decline in PD.
Methods
We correlated baseline CSF DDC, detected using the proximity extension assay, with Montreal Cognitive Assessment (MoCA) score using longitudinal data from 3 cohorts: Biopark, PPMI, and PDBP.
Results
DDC was significantly associated with cognitive decline in both the Biopark cohort (P‐value < 0.0001) and the PDBP/PPMI cohorts (P‐value < 0.0001). The results were still significant after correcting for levodopa‐equivalent daily dose in the Biopark cohort (P‐value < 0.0001) and when the analysis was restricted to the de novo subjects, both in Biopark (P‐value: 0.0065) and PPMI (P‐value<0.0001) cohorts.
Conclusions
CSF DDC is a potential biomarker for the prediction of cognitive decline in PD patients.